Literature DB >> 18682503

Loss-of-function mutations in the genes encoding prokineticin-2 or prokineticin receptor-2 cause autosomal recessive Kallmann syndrome.

Ana Paula Abreu1, Ericka Barbosa Trarbach, Margaret de Castro, Elaine Maria Frade Costa, Beatriz Versiani, Maria Tereza Matias Baptista, Heraldo Mendes Garmes, Berenice Bilharinho Mendonca, Ana Claudia Latronico.   

Abstract

CONTEXT: Physiological activation of the prokineticin pathway has a critical role in olfactory bulb morphogenesis and GnRH secretion in mice.
OBJECTIVE: To investigate PROK2 and PROKR2 mutations in patients with hypogonadotropic hypogonadism (HH) associated or not with olfactory abnormalities.
DESIGN: We studied 107 Brazilian patients with HH (63 with Kallmann syndrome and 44 with normosmic HH) and 100 control individuals. The coding regions of PROK2 and PROKR2 were amplified by PCR followed by direct automatic sequencing.
RESULTS: In PROK2, two known frameshift mutations were identified. Two brothers with Kallmann syndrome harbored the homozygous p.G100fsX121 mutation, whereas one male with normosmic HH harbored the heterozygous p.I55fsX56 mutation. In PROKR2, four distinct mutations (p.R80C, p.Y140X, p.L173R, and p.R268C) were identified in five patients with Kallmann syndrome and in one patient with normosmic HH. These mutations were not found in the control group. The p.R80C, p.L173R, and p.R268C missense mutations were identified in the heterozygous state in the HH patients and in their asymptomatic first-degree relatives. In addition, no mutations of FGFR1, KAL1, GnRHR, KiSS-1, or GPR54 were identified in these patients. Notably, the new nonsense mutation (p.Y140X) was identified in the homozygous state in an anosmic boy with micropenis, bilateral cryptorchidism, and high-arched palate. His asymptomatic parents were heterozygous for this severe defect.
CONCLUSION: We expanded the repertoire of PROK2 and PROKR2 mutations in patients with HH. In addition, we show that PROKR2 haploinsufficiency is not sufficient to cause Kallmann syndrome or normosmic HH, whereas homozygous loss-of-function mutations either in PROKR2 or PROK2 are sufficient to cause disease phenotype, in accordance with the Prokr2 and Prok2 knockout mouse models.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18682503     DOI: 10.1210/jc.2008-0958

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  44 in total

1.  Olfactory phenotypic spectrum in idiopathic hypogonadotropic hypogonadism: pathophysiological and genetic implications.

Authors:  Hilana M Lewkowitz-Shpuntoff; Virginia A Hughes; Lacey Plummer; Margaret G Au; Richard L Doty; Stephanie B Seminara; Yee-Ming Chan; Nelly Pitteloud; William F Crowley; Ravikumar Balasubramanian
Journal:  J Clin Endocrinol Metab       Date:  2011-11-09       Impact factor: 5.958

2.  Commentary: the year in endocrine genetics for basic scientists.

Authors:  William F Crowley
Journal:  Mol Endocrinol       Date:  2011-11-22

3.  Evidence that prokineticin receptor 2 exists as a dimer in vivo.

Authors:  Sara Marsango; Maria Carmela Bonaccorsi di Patti; Donatella Barra; Rossella Miele
Journal:  Cell Mol Life Sci       Date:  2010-12-14       Impact factor: 9.261

Review 4.  The role of prokineticins in the pathogenesis of hypogonadotropic hypogonadism.

Authors:  Ana Paula Abreu; Ursula B Kaiser; Ana Claudia Latronico
Journal:  Neuroendocrinology       Date:  2010-05-21       Impact factor: 4.914

5.  An ancient founder mutation in PROKR2 impairs human reproduction.

Authors:  Magdalena Avbelj Stefanija; Marc Jeanpierre; Gerasimos P Sykiotis; Jacques Young; Richard Quinton; Ana Paula Abreu; Lacey Plummer; Margaret G Au; Ravikumar Balasubramanian; Andrew A Dwyer; Jose C Florez; Timothy Cheetham; Simon H Pearce; Radhika Purushothaman; Albert Schinzel; Michel Pugeat; Elka E Jacobson-Dickman; Svetlana Ten; Ana Claudia Latronico; James F Gusella; Catherine Dode; William F Crowley; Nelly Pitteloud
Journal:  Hum Mol Genet       Date:  2012-07-05       Impact factor: 6.150

Review 6.  Neonatal gonadotropin therapy in male congenital hypogonadotropic hypogonadism.

Authors:  Claire Bouvattier; Luigi Maione; Jérôme Bouligand; Catherine Dodé; Anne Guiochon-Mantel; Jacques Young
Journal:  Nat Rev Endocrinol       Date:  2011-10-18       Impact factor: 43.330

Review 7.  The role of the prokineticin 2 pathway in human reproduction: evidence from the study of human and murine gene mutations.

Authors:  Cecilia Martin; Ravikumar Balasubramanian; Andrew A Dwyer; Margaret G Au; Yisrael Sidis; Ursula B Kaiser; Stephanie B Seminara; Nelly Pitteloud; Qun-Yong Zhou; William F Crowley
Journal:  Endocr Rev       Date:  2010-10-29       Impact factor: 19.871

8.  Genetic overlap in Kallmann syndrome, combined pituitary hormone deficiency, and septo-optic dysplasia.

Authors:  Taneli Raivio; Magdalena Avbelj; Mark J McCabe; Christopher J Romero; Andrew A Dwyer; Johanna Tommiska; Gerasimos P Sykiotis; Louise C Gregory; Daniel Diaczok; Vaitsa Tziaferi; Mariet W Elting; Raja Padidela; Lacey Plummer; Cecilia Martin; Bihua Feng; Chengkang Zhang; Qun-Yong Zhou; Huaibin Chen; Moosa Mohammadi; Richard Quinton; Yisrael Sidis; Sally Radovick; Mehul T Dattani; Nelly Pitteloud
Journal:  J Clin Endocrinol Metab       Date:  2012-02-08       Impact factor: 5.958

Review 9.  The genetic basis of female reproductive disorders: etiology and clinical testing.

Authors:  Lawrence C Layman
Journal:  Mol Cell Endocrinol       Date:  2013-03-14       Impact factor: 4.102

10.  Prioritizing genetic testing in patients with Kallmann syndrome using clinical phenotypes.

Authors:  Flavia Amanda Costa-Barbosa; Ravikumar Balasubramanian; Kimberly W Keefe; Natalie D Shaw; Nada Al-Tassan; Lacey Plummer; Andrew A Dwyer; Cassandra L Buck; Jin-Ho Choi; Stephanie B Seminara; Richard Quinton; Dorota Monies; Brian Meyer; Janet E Hall; Nelly Pitteloud; William F Crowley
Journal:  J Clin Endocrinol Metab       Date:  2013-03-26       Impact factor: 5.958

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.